Adjuvant Immunotherapy in High-Risk Renal Cell Carcinoma
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
CheckMate-914 Phase III Trial
- July 29, 2022
CheckMate-914 Phase III trial evaluated dual immune checkpoint blockade (nivolumab plus ipilimumab) as adjuvant therapy in patients with intermediate-to-high risk renal cell carcinoma after radical or partial nephrectomy.
Clinical Rationale
Adjuvant immunotherapy for high-risk RCC addresses recurrence prevention in surgically resected disease, attempting to improve disease-free survival through immune activation against micrometastatic disease.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.